MGMT inhibitor combination for the treatment of neoplastic disorders
US8791081B2 · kind B2 · utility
0Cited by
2References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 29, 2008 |
| Grant date | Jul 29, 2014 |
| Priority date | — |
| Expiry date | Oct 14, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.